Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody

While glyco-engineered monoclonal antibodies (mAbs) with improved antibody-dependent cell-mediated cytotoxicity (ADCC) are reaching the market, extensive efforts have also been made to improve their pharmacokinetic properties to generate biologically superior molecules. Most therapeutic mAbs are hum...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Monnet, Céline, Jorieux, Sylvie, Souyris, Nathalie, Zaki, Ouafa, Jacquet, Alexandra, Fournier, Nathalie, Crozet, Fabien, de Romeuf, Christophe, Bouayadi, Khalil, Urbain, Rémi, Behrens, Christian K, Mondon, Philippe, Fontayne, Alexandre
Formato: Artigo
Idioma:Inglês
Publicado em: Landes Bioscience 2014
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3984331/
https://ncbi.nlm.nih.gov/pubmed/24492301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.27854
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados